New York, NY (PRWEB) July 20, 2014
Nearly 2,000 NaturaLyte and GranuFlo lawsuits (http://www.thegranuflolawsuit.com ) have now been filed in a federal litigation involving the dialysis medications, Bernstein Liebhard LLP reports.
A Case List updated on July 15th indicates that 1,942 lawsuits are now pending in the U.S. District Court, District of Massachusetts, where a federal proceeding is underway. All lawsuits in this litigation were filed after the U.S. Food and Drug Administration (FDA) issued a Class I recall of GranuFlo and NaturaLyte due to their alleged potential to cause serious cardiovascular events. According to plaintiffs, these may include heart attacks, strokes and sudden cardiac death. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“Our Firm is representing numerous clients now involved in the federal GranuFlo proceeding underway in Massachusetts, and we continue to speak with individuals whose loved ones were allegedly harmed by the dialysis medications,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free and confidential GranuFlo lawsuit evaluations to individuals who allegedly suffered serious heart injuries after taking the dialysis drugs.
According to court documents in the District of Massachusetts, plaintiffs in GranuFlo and NaturaLyte lawsuits similarly accuse Fresenius of failing to adequately warn dialysis patients and their doctors about injuries that may stem from its products. Plaintiffs further allege that the companies continued to promote its products even after becoming aware of risks.
On March 29, 2012, Fresenius issued an Urgent Product Notification that warned of GranuFLo and NaturaLyte’s association with metabolic alkalosis, a condition that may be associated with serious heart problems. This may be caused by the medications’ elevated amount of an ingredient the body converts to bicarbonate. Two months later, the FDA announced a Class I recall of the medications after finding that hundreds of people suffered cardiovascular injuries after taking GranuFlo and NaturaLyte.
A New York Times report published shortly after the June 2012 recall indicates that the FDA was investigating Fresenius Medical Care, after finding that the company knew about hundreds of patient deaths that followed use of the medications.*
Individuals who allegedly suffered heart attacks, strokes, or other life-threatening heart events within 72 hours of using GranuFlo and NaturaLyte in dialysis may be entitled to compensation for their injuries. Learn more about lawsuits filed after the GranuFlo recall when you visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP